Quantinno Capital Management LP boosted its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 33.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,892 shares of the financial services provider’s stock after purchasing an additional 4,939 shares during the quarter. Quantinno Capital Management LP’s holdings in iShares Biotechnology ETF were worth $3,359,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of IBB. Darwin Wealth Management LLC bought a new position in shares of iShares Biotechnology ETF in the second quarter valued at about $25,000. Basepoint Wealth LLC bought a new stake in shares of iShares Biotechnology ETF during the 4th quarter worth about $26,000. Cary Street Partners Financial LLC bought a new stake in shares of iShares Biotechnology ETF during the 4th quarter worth about $29,000. Copia Wealth Management acquired a new position in iShares Biotechnology ETF in the 4th quarter valued at about $34,000. Finally, Caitlin John LLC acquired a new position in iShares Biotechnology ETF in the 4th quarter valued at about $34,000. 62.45% of the stock is currently owned by institutional investors and hedge funds.
iShares Biotechnology ETF Stock Performance
Shares of IBB stock opened at $197.71 on Friday. The firm has a 50 day moving average price of $183.84 and a two-hundred day moving average price of $175.35. iShares Biotechnology ETF has a 12-month low of $131.36 and a 12-month high of $199.05.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Read More
- Five stocks we like better than iShares Biotechnology ETF
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
